INTRODUCTION
============

The core network of transcription factors (TFs) and the main events that lead to heart formation have been conserved in evolution. The cardiac TFs GATA4, NKX2.5, and TBX5 are central to human heart development (Clark et al.,[@b17]; Olson,[@b56]; Srivastava,[@b73]; Nemer,[@b55]). Mutations in these genes significantly perturb heart development resulting in Congenital Heart Diseases (CHDs). In *Drosophila*, mutations in the homologues of these genes, *tinman* (*tin*; the fly *NKX2.5* homologue), *pannier* (*pnr*; the fly *GATA4* homologue), *Dorsocross1-3* (*Doc1-3*; most closely related to *Tbx6*), and *midline* (*mid*; the fly *TBX20* homologue), affect the formation of the cardiac tube (reviewed in Reim and Frasch,[@b65]). Mutations in the two cardiac TFs GATA4 and NKX2.5 impair their functions leading to CHDs (Schott et al.,[@b71]; Garg et al.,[@b30]). In humans, *TBX5* is essential for heart and forelimb development and mutations in this gene lead to a developmental disorder called Holt-Oram syndrome (Basson et al.,[@b5]; Li et al.,[@b45]; Mori and Bruneau,[@b53]). Mutations in TBX5 significantly alter its DNA-binding, protein--protein interaction and transcriptional activities (Ghosh et al.,[@b31]; Hiroi et al.,[@b36]; Fan et al.,[@b23]; Garg et al.,[@b30]). TBX5, alone or in combination with NKX2.5 and GATA4, regulates the transcription of *NPPA, MYH6* and *CX40*, genes that are important for cardiomyocyte differentiation (Bruneau et al.,[@b9]; Hiroi et al.,[@b36]; Ching et al.,[@b15]). Functional interactions between TBX5 and GATA4 are important for heart development and compound heterozygous mice show significant down-regulation of *Myh6* (Maitra et al.,[@b50]), which encodes a sarcomeric protein associated with cardiomyopathy and other congenital heart disorders (Carniel et al.,[@b13]; Ching et al.,[@b15]). Cardiac TFs Tbx5 and Gata4 in combination with Baf60c or Mef2c can also drive ectopic differentiation of mouse mesoderm or fibroblast cells into beating cardiac myocytes (Takeuchi and Bruneau,[@b74]; Ieda et al.,[@b38]), thereby suggesting the functional importance of these TFs and also their potential for future regenerative medicine.

Although functional cooperation between these cardiac TFs has been well documented, to date there are very few direct targets characterized. Two well-characterized targets are *NPPA* and *MYH6. NPPA* is a downstream target of GATA4 (Durocher et al.,[@b22]; Lee et al.,[@b43]), NKX2.5 (Durocher et al.,[@b21]), and TBX5 (Hiroi et al.,[@b36]). Mutations in either *NKX2.5* or *TBX5* severely reduce the transcription of *NPPA* (Zhu et al.,[@b83]; Ghosh et al.,[@b31]; Hiroi et al.,[@b36]; Fan et al.,[@b23]), whereas the transcription of *MYH6* is impaired by *TBX5* or *GATA4* mutations (Garg et al.,[@b30]; Ching et al.,[@b15]). The enhancers of these genes are invaluable tools for understanding the molecular mechanisms of heart development and disorders. Most commonly, these studies were conducted in *in vitro* tissue culture cells following transfection of the relevant constructs. Mutations in these TFs are pleiotropic and show different degrees of penetrance. Thus, their *in vivo* study in vertebrates is a difficult task.

It is known that regulatory regions identified in one organism can function in a heterologous organism (Awgulewitsch and Jacobs,[@b3]; Malicki et al.,[@b51]; Frasch et al.,[@b26]; Pöpperl et al.,[@b58]; Haerry and Gehring,[@b33],[@b34]; Keegan et al.,[@b40]; Xu et al.,[@b77]; Brugger et al.,[@b8]). For example, the autoregulatory elements of *Drosophila deformed* and of its mammalian homologue *Hoxb-4* are functionally very conserved as they are able to function in each heterologous organism (the fly homologue in mice and the human one in flies) (Awgulewitsch and Jacobs,[@b3]; Malicki et al.,[@b51]); the r4 enhancer of mouse *Hoxb-1* functions as an auto-regulatory element in *Drosophila* embryos (Pöpperl et al.,[@b58]); the eye-specific enhancer of *Drosophila eyeless* directs eye- and CNS-specific expression in transgenic mice and the mouse *Pax6* P1 upstream region directs expression in *Drosophila* photoreceptors (Xu et al.,[@b77]). All these examples highlight a high level of evolutionary conservation of the transcriptional machinery between insects and mammals.

In the present work, we show specific reporter gene up-regulation of two human enhancers by the mammalian TFs GATA4, Nkx2.5, and TBX5 in *Drosophila* embryos. *Drosophila* has been largely used as a model to study homologies of signaling and regulatory pathways that govern organogenesis in vertebrates and invertebrates. Rescue experiments where a *Drosophila* TF is replaced by its vertebrate homologue or where a vertebrate regulatory sequence is activated by a *Drosophila* TF have been performed. Nevertheless, it is worth mentioning that such assayed vertebrate regulatory sequences belong to TFs or to signaling molecules at the top of the pyramid of cues that lead to organogenesis. On the contrary, this has rarely been shown for downstream effector genes, which are the actual "realizators" (Garcia Bellido, [@b30]) of organogenesis. Since regulatory regions identified in one organism might function in a heterologous organism, we decided to investigate if this could be true also for the regulatory regions of downstream effector genes involved in human cardiogenesis. In this work, we show that the mammalian TFs GATA4, Nkx2.5, and TBX5 are able to up-regulate their natural target enhancers *in vivo* in *Drosophila* embryos.

RESULTS AND DISCUSSION
======================

In order to determine whether human enhancers of cardiac realizator genes could be active in *Drosophila*, we first selected two human enhancers belonging to genes that are involved in a widely described human pathology, namely CHDs, the regulation of which is well known. The two enhancers belong to the *NPPA* and *MYH6* human genes. ANF, the product of *NPPA*, is one of the earliest markers of cardiac differentiation expressed in the forming ventricular and atrial chamber myocardium (Christoffels et al.,[@b16]). The *NPPA* promoter has served as a model for studying the regulatory mechanisms of cardiac TFs. A number of cardiac TFs such as GATA4 (Durocher et al.,[@b22]), NKX2.5 (Durocher et al.,[@b21]) and TBX5 (Ghosh et al.,[@b31]; Hiroi et al.,[@b36]) have been shown to interact with an *NPPA* enhancer. *MYH6* is another important structural and functional gene mainly expressed in the atrium (Kurabayashi et al.,[@b42]). In humans, mutations in this gene are associated with atrial septal defects (Ching et al.,[@b15]) and cardiomyopathy (Carniel et al.,[@b13]). The *MYH6* enhancer is regulated by the TFs GATA4 (Molkentin et al.,[@b52]), TBX5 (Ching et al.,[@b15]), and MEF2 (Ghosh et al.,[@b32]).

In our study, we have used a 300-bp fragment immediately upstream of the *NPPA* promoter (called ANF300) because this enhancer fragment was shown to be activated *in vitro* by the three cardiac-specific TFs TBX5, NKX2.5, and GATA4 (Durocher et al.,[@b22]; Bruneau et al.,[@b9]; Ghosh et al.,[@b31]). Similarly, the 4.5-Kb fragment of *MYH6* we used has also been shown to be activated *in vitro* by GATA 4 (Molkentin et al.,[@b52]), by TBX5 (Ching et al.,[@b15]), and by TBX5 in cooperation with MEF2C (Ghosh et al.,[@b32]). We cloned the ANF300 and MYH6 enhancers in the pH-Stinger vector (Barolo et al.,[@b4]) upstream of the hs43 promoter directing nGFP expression. No nGFP expression was detected in transgenic embryos by *in situ* hybridization ([Figs. 1](#fig01){ref-type="fig"}A, B, [2](#fig02){ref-type="fig"}A, B). This indicates that wild-type levels of *Drosophila* TFs are unable to up-regulate these two enhancers either because the levels of GFP expression driven by the endogenous TFs are too low to be detected or because the endogenous TFs are busy taking care of their normal targets (a sort of threshold effect). By contrast, the over-expression of *GATA4, Nkx2.5*, or *TBX5* in embryos using the UAS/GAL4 system (Brand and Perrimon,[@b7]) specifically activated *nGFP* in the same way through both the ANF300 ([Fig. 1](#fig01){ref-type="fig"}) and MYH6 ([Fig. 2](#fig02){ref-type="fig"}) enhancers. When the three TFs are over-expressed through the *Hand-GAL4* driver (Albrecht et al.,[@b2]; Sellin et al.,[@b72]), *GFP* expression is detected in the cardiac tube and in the visceral mesoderm ([Figs. 1](#fig01){ref-type="fig"}E--J, [2](#fig02){ref-type="fig"}E--J), in the same domains as *UAS-GFP* expression ([Figs. 1](#fig01){ref-type="fig"}C,D, [2](#fig02){ref-type="fig"}C,D). This indicates that the three human TFs are able to up-regulate their human targets in *Drosophila* and that *MYH6* is a putative target of *Nkx2.5*, which has not been reported before. No GFP expression was observed in embryos carrying only the reporter and the *Hand-GAL4* driver ([Figs. 1](#fig01){ref-type="fig"}A,B, [2](#fig02){ref-type="fig"}A,B) or when over-expression was achieved in the Central Nervous System with the *elav-GAL4* driver (data not shown), which did not lead to lethality.

![GATA4, Nkx2.5, and TBX5 transactivate the ANF300 enhancer in *Drosophila* embryos. Detection of *GFP* expression driven by the ANF300 enhancer by *in situ* hybridization using HRP staining. All embryos are shown with the anterior end to the left. Left column: Stage 3--14 embryos. Right column: Stage 15--16 embryos (dorsal side up). All embryos carry the *ANF-hs43-nGFP* reporter and the *Hand-GAL4* driver. In wild-type embryos (**A, B**), no *GFP* is detected. In embryos carrying also the *UAS-GFP* (**C, D**), *UAS-GATA4* (**E, F**), *UAS-Nkx2.5* (**G, H**), or *UAS-TBX5* (**I, J**) transgene, *GFP* is detected in the cardiac tube (block arrows) and in the visceral mesoderm (arrows). Staining with the sense *GFP* probe did not produce any signal except for salivary glands (arrowheads, data not shown).](dvdy0241-0190-f1){#fig01}

![GATA4, Nkx2.5, and TBX5 transactivate the MYH6 enhancer in *Drosophila* embryos. Detection of GFP expression driven by the MYH6 enhancer by *in situ* hybridization using HRP staining. Left column: Stage-13--14 embryos. Right column: Stage-15--16 embryos (dorsal side up). All embryos carry the *MYH6-hs43-nGFP* reporter and the *Hand-GAL4* driver. In wild-type embryos (**A, B**), no *GFP* is detected. In embryos carrying also the *UAS-GFP* (**C, D**), *UAS-GATA4* (**E, F**), *UAS-Nkx2.5* (**G, H**), or *UAS-TBX5* (**I, J**) transgene, *GFP* is detected in the cardiac tube (block arrows) and in the visceral mesoderm (arrows). Staining with the sense *GFP* probe did not produce any signal except for salivary glands (arrowheads, data not shown).](dvdy0241-0190-f2){#fig02}

We extracted mRNA from the embryos of the same genotypes as those used for the *in situ* hybridization shown in [Figure 1](#fig01){ref-type="fig"}. We reverse-transcribed it and used it as a template in PCR reactions amplified with GFP oligonucleotides. We did not observe any amplification product in embryos carrying only the reporter and the *Hand-GAL4* transgenes ([Fig. 3](#fig03){ref-type="fig"}A, lane 3), whereas we detected a specific band of the expected GFP size ([Fig. 3](#fig03){ref-type="fig"}A, lane 7) in the embryos that also carry the *UAS-GATA4, UAS-Nkx2.5*, or *UAS-TBX5* effector constructs ([Fig. 3](#fig03){ref-type="fig"}A, lanes 4--6). The *rp49* housekeeping control indicates that cDNA is equally present in all samples ([Fig. 3](#fig03){ref-type="fig"}B). The same RT-PCR experiment has been done for the MYH6 enhancer and gave the same results (data not shown). Thus, *GFP* is indeed up-regulated by the three TFs considered.

![Detection of GFP by RT-PCR. RT-PCR was performed on the same embryos as those of [Figure 1](#fig01){ref-type="fig"}. **A:** RT-PCR detection of *GFP*. **B:** RT-PCR detection of the *rp49* housekeeping gene. 1, mock PCR; 2, *white*; 3, *Hand-GAL4; ANF300MYH6-hs43-nGFP*; 4, *Hand-GAL4; ANF300MYH6-hs43-nGFP* + *UAS-GATA4*; 5, *Hand-GAL4; ANF300MYH6-hs43-nGFP* + *UAS-Nkx2.5*; 6, *Hand-GAL4; ANF300MYH6-hs43-nGFP* + *UAS-TBX5*; 7, *Hand-GAL4; ANF300MYH6-hs43-nGFP* + *UAS-GFP*. A specific *GFP* band is detected only in *GATA4, Nkx2.5*, and *TBX5* overexpressing embryos (lanes 4--6) and in the positive control (lane 7).](dvdy0241-0190-f3){#fig03}

The *Drosophila* system we propose allows analyzing the functions of human TFs *in vivo. In vitro*, not all cell types are transfected with the same efficiency and, in some instances, overexpression of the TFs causes spurious activity. Using *Drosophila* transgenics as a model overrides variability, for example due to transfection efficiency, because in transgenic flies all the cells in a tissue carry both the reporter and the effector constructs, which are up-regulated all at the same level through the UAS/GAL4 system. Consequently, in this system the molecular interactions observed can be studied at a higher level of precision. In addition, a strong potential of the present model might come from the combinatorial and mutational assays of TFs on their target promoters, which are not easily undertaken in tissue culture cells because of the variability in transfection efficiency especially when multiple constructs are used.

*pnr* and *tin* are the fly homologues of human *GATA4* and *NKX2.5*, respectively. The *Drosophila pnr, tin*, and *Tbx* genes are known to auto-regulate and to cross-regulate each other (Gajewski et al.,[@b29]; Klinedinst and Bodmer,[@b41]; Qian et al.,[@b59]; Reim and Frasch,[@b64]; Reim et al.,[@b67]). Similarly, NKX2.5 regulates the expression of human *GATA4* (Riazi et al.,[@b68]) and GATA4 also regulates transcription of *NKX2.5* through an upstream *NKX2.5* enhancer (Lien et al.,[@b47]). So far, there is no report on an autoregulatory role for *NKX2.5* and *GATA4*. To rule out a possible endogenous regulatory circuit, we first determined whether *tin* (the fly homologue of *NKX2.5*) is able to up-regulate the ANF300 and MYH6 enhancers. [Figure 4](#fig04){ref-type="fig"} shows the up-regulation of the two enhancers by overexpression of either *Nkx2.5* or *tin* in the whole mesoderm using the *24B-GAL4* driver, which directs expression in the whole mesoderm ([Fig. 4](#fig04){ref-type="fig"}; see Supp. [Fig. S1](#SD1){ref-type="supplementary-material"}, which is available online) (Zaffran et al.,[@b80]). Thus, Tin has the same regulatory ability as its Nkx2.5 homologue in the regulation of the ANF300 and MYH6 enhancers. GATA4, Nkx2.5, and TBX5 could up-regulate the two enhancers through the indirect activation of their fly homologues. To rule out this possibility, we looked at the expression of the fly endogenous genes *pnr* (*GATA4* homologue), *tin* (*NKX2.5* homologue), *midline* (*TBX20* homologue), and *Doc1* (*TBX6* homologue; there is no true *Drosophila* homologue of *TBX5*) in embryos ectopically activating *GATA4, Nkx2.5*, or *TBX5*. By *in situ* hybridization (for *pnr, Doc1*, and *mid*) or immunohistochemistry (for *tin*), we did not see a change in expression of these endogenous fly genes in germ band--extended and in germ band--retracted embryos upon *GATA4, Nkx2.5*, or *TBX5* over-expression in the cardiac, somatic, and visceral mesoderm through the *24B-GAL4* driver ([Fig. 5](#fig05){ref-type="fig"}). This indicates that the regulation of the two tested enhancers by the three mammalian TFs is not indirect.

![*tin* overexpression transactivates the ANF300 and MYH6 enhancers. Detection of *GFP* expression driven by the ANF300 and MYH6 enhancers upon *tin* overexpression by *in situ* hybridization. Left two columns: Germ band--extended embryos. Right two columns: Germ band--retracted embryos. Embryos carrying only the reporter and *GAL4* transgenes (top row) do not show *GFP* expression. Embryos overexpressing *GFP* (second row), *Nkx2.5* (third row), or *tin* (fourth row) through the *24B-GAL4* driver show *GFP* expression in the somatic and visceral (arrows) mesoderm. Overexpression of *tin* is detected by immunohistochemistry using anti-Tin antibodies (bottom row).](dvdy0241-0190-f4){#fig04}

![Endogenous *Drosophila* TFs are not mis-expressed by the over-expression of *GATA4, Nkx2.5*, or *TBX5*. Detection of *tin* protein by immunohistochemistry and of *pnr, Doc1*, and *mid* transcripts by *in situ* hybridization in control embryos (top) and in embryos overexpressing *GATA4, Nkx2.5*, or *TBX5* (see left) in the whole mesoderm through the *24B-GAL4* driver. **A:** Germ band--extended embryos. **B:** Germ band--retracted embryos. Each gene is expressed at normal levels in all embryos.](dvdy0241-0190-f5){#fig05}

Several human and murine enhancers have been shown to be active in *Drosophila*. Most of the reporter constructs used in the regulatory studies on the evolutionary conservation of enhancers reported in the Introduction section (Awgulewitsch and Jacobs,[@b3]; Malicki et al.,[@b51]; Frasch et al.,[@b26]; Pöpperl et al.,[@b58]; Haerry and Gehring,[@b33],[@b34]; Keegan et al.,[@b40]; Xu et al.,[@b77]; Brugger et al.,[@b8]) utilized the TATA promoter *hs43* (the *Drosophila hsp70* promoter deleted of the Pelham heat-inducible box) that we used in our studies. This promoter is silent in *Drosophila*. It has been used in numerous studies on many types of *Drosophila* and mammalian TFs over many years (Qian et al.,[@b60],[@b61]; Capovilla et al.,[@b11]; Chan et al.,[@b14]; Capovilla and Botas,[@b10]; Hiromi and Gehring,[@b37]; Wagner-Bernholz et al.,[@b76]; Vachon et al.,[@b75]; Gajewski et al.,[@b27]; Ranganayakulu et al.,[@b63]; Li et al.,[@b46]; Ryoo et al.,[@b70]; Han et al.,[@b35]; Sellin et al.,[@b72]; Ryan et al.,[@b69]). In addition, several mammalian TFs have been shown to function in *Drosophila* as their fly homologues (Luo et al.,[@b49]; Albagli et al.,[@b1]; Ludlow et al.,[@b48]; Deshpande et al.,[@b20]; Leuzinger et al.,[@b44]; Nagao et al.,[@b54]; D\'Souza et al.,[@b19]; Fox et al.,[@b25]). In most of these studies, the *Drosophila* or mammalian TFs were over-expressed through the UAS/GAL4 method we used. Thus, it is very likely that the GFP expression we observed comes from a direct interaction between the TFs over-expressed and the two human enhancers studied, which is supported by the results reported in [Figure 5](#fig05){ref-type="fig"}. To our knowledge, this is the first report of human enhancers being activated by human TFs in flies and it highlights the high evolutionary conservation of the regulatory functions of these molecules.

We determined whether *GATA4, Nkx2.5*, or *TBX5* over-expression could cause developmental defects. To this aim, we over-expressed the three TFs in the whole mesoderm (through the *24B-GAL4* driver), in the eyes (through the *GMR-GAL4* driver), and in the wings (through the *vestigial-GAL4* driver). Over-expression of each of the three TF in the mesoderm is lethal. Over-expression in eyes and wings causes developmental defects, as both are very reduced ([Fig. 6](#fig06){ref-type="fig"}). For *GMR-GAL4*, the penetrance is complete at 28°C and at 18°C for all three TFs (Supp. [Fig. S2](#SD2){ref-type="supplementary-material"}). At 18°C, the overexpression of Nkx2.5 in the eye shows variable expressivity (data not shown). Finally, we observed that very similar phenotypes in both eyes and wings are elicited by the overexpression of *pnr* (with 100% penetrance at all temperatures), but not of *tin* (data not shown). This is consistent with the fact that *GATA4* is the true orthologue of *pnr* (Gajewski et al.,[@b28]), whereas *Nkx2.5* is not able to functionally replace *tin* in all its developmental roles (Park et al.,[@b57]; Ranganayakulu et al.,[@b63]). The fact that overexpression of the three TFs leads to the same developmental defects suggests that they act in the same developmental pathway. Because the phenotypes elicited are viable and very easy to score, the over-expression of these TFs could be used to carry out modifier screens in order to identify novel interactors, as as it has been successfully done for other gene products (Fernandez-Funez et al.,[@b24]; Bilen and Bonini,[@b6]; Cukier et al.,[@b18]; Jung et al.,[@b39]).

![Developmental defects caused by *GAT4, Nkx2.5*, or *TBX5* over-expression in eyes and in wings. Reduced eyes and wings caused by the overexpression of *GATA4* (**C, D**), *Nkx2.5* (**E, F**) or *TBX5* (**G, H**) in the eye through the *GMR-GAL4* driver (C, E, G) or in the wing through the *vg-GAL4* driver (D, F, H). Top: Control flies carrying only the *GMR-GAL4* (**A**) or **vg-GAL4** (**B**) drivers. All flies were raised at 27°C, but phenotypic effects were visible also at 18°C (data not shown and Supp. [Fig. S2](#SD2){ref-type="supplementary-material"}).](dvdy0241-0190-f6){#fig06}

To our knowledge, this is the first report of human TFs regulating their natural downstream effector targets in *Drosophila*. This system might be used to carry out structural/functional studies for combinatorial analyses of multiple TFs that would not be easily undertaken *in vitro*, because transfection efficiency is limiting when more than two factors are transfected. This assay may allow determining clearly the genetic functions of mutant forms of these TFs or of their targets involved in CHDs, to define unambiguously *in vivo* their inter-relationships and genetic features (e.g., dominance), which may help to understand the different phenotypes observed among CHDs patients.

EXPERIMENTAL PROCEDURES
=======================

The GAL4 lines used are: *Hand*-*GAL4* (Albrecht et al., [@b2]; Sellin et al., [@b73]), P{GawB}*how*\[24B\] (*24B-GAL4*), *GMR-GAL4, elav-GAL4*, and *vestigial-GAL4*.

The ANF 300-bp enhancer fragment was amplified from the pGL3 ANF300 plasmid (Ghosh et al.,[@b31]) using the oligonucleotides 5′-GG[TCTAGA]{.ul}CAGC GTCGAGGAGAAAGAAT-3′ (carrying a XbaI site) and 5′-TT[GGATCC]{.ul}AGC TCTCCAAGCACGCAG-3′ (carrying a BamHI site). The 4.5-kb MYH6 enhancer was amplified from the pGL3 MYH6 4.5 plasmid (Ching et al.,[@b15]) using the oligonucleotides 5′-CC[TCTAGA]{.ul}GAAGCCGAGATCCT GACTCCAGACTCTTCT-3′ (carrying a XbaI site) and 5′-CC[GGATCC]{.ul}CCT CTGTCTAAATTTGGAGTCCTTCCGG AG-3′ (carrying a BamHI site). Both enhancers were cloned in the XbaI and BamHI sites of pH-Stinger (Barolo et al.,[@b4]) upstream of the minimal *hs43* promoter driving *nGFP* expression to generate the *ANF300-hs43-nGFP* and *MYH6-hs43-nGFP* reporters.

To generate the *UAS-GATA4* construct, the *GATA4* cDNA was excised from pcDNA3.1 Zeo(-) GATA4 (T. K. Ghosh, unpublished data) with EcoRI and cloned in the EcoRI site of pUAST (Brand and Perrimon,[@b7]). The orientation was verified with BamHI to select a clone with the orientation appropriate for protein synthesis. The TBX5 cDNA was excised from pcDNA.1zeo(+) TBX5 (Ghosh et al.,[@b31]) with XhoI and EcoRI and cloned in the NheI and BamHI sites of pBluescript KS+. From this construct, it was then excised using NotI and KpnI and cloned in the NotI and KpnI sites of pUAST to generate *UAS-TBX5. ANF300-hs43-nGFP*, and *MYH6-hs43-nGFP* transgenic flies were generated in the laboratory by standard methods. *UAS-GATA4* and *UAS-TBX5* transgenic flies were generated by Best Gene Inc. (Chino Hills, CA). *UAS-Nkx2.5* (Zaffran et al.,[@b81]) flies and *UAS-tin* flies (Yin and Frasch,[@b78]) were a gift of Manfred Frasch. At least two independent reporter and UAS lines were analyzed for each experiment.

The GAL4 lines used are: *Hand*-*GAL4* (Albrecht et al., [@b2]; Sellin et al., [@b37]), P{GawB}*how*\[24B\] (*24B-GAL4*), *GMR-GAL4, elav-GAL4*, and *vestigial-GAL4*.

Crosses and Embryo Staining
---------------------------

Double-balanced *Hand-GAL4; ANF300-hs43-nGFP* and *Hand-GAL4; MYH6-hs43-nGFP* stocks were generated by standard procedures. Males of these stocks were crossed to *UAS-GFP* (Blooomington stock n. 1521), *UAS-GATA4, UAS-Nkx2.5*, or *UAS-TBX5* females at 27°C. Progeny embryos were dechorionated in 50% bleach, fixed in 4% formaldehyde, devitellinized in 100% methanol, and stored in 100% ethanol. All probes were made using the Riboprobe Combination System kit (Promega, Madison, WI) and the DIG RNA Labeling Mix (Roche, Indianapolis, IN). To make GFP probes, the GFP cDNA was excised from pStinger (Barolo et al.,[@b4]) with EcoRI and XbaI and cloned in the EcoRI and XbaI sites of pGEM. *GFP* sense and antisense probes were made by linearizing with HindIII and transcribing with SP6 or by linearizing with EcoRI and transcribing with T7, respectively. The *Doc2, mid*, and *pnr* antisense probes were made as follows: the *Doc2* cDNA cloned in pNB40 (Reim et al.,[@b66]) was linearized with SmaI and transcribed with T7, the *mid* cDNA plasmid cloned in pFLC (Reim et al.,[@b67]) was linearized with XhoI and transcribed with T3, and the *pnr* cDNA plasmid (Ramain et al.,[@b62]) cloned in pBluescript was linearized with HindIII and transcribed with T3. Embryos were stained using the TSA Plus Biotin System (Perkin Elmer, Waltham, MA) with minor modifications available upon request. Immunohistochemistry was carried out as previously described (Capovilla et al.,[@b12]) with anti-Tin antibodies (Yin et al.,[@b79]) at a 1:1,000 dilution.

RT PCR
------

Total RNA was extracted from 30 μl of dechorionated 12--24-hr embryos using PureZOL RNA Isolation Reagent (BioRad, Hercules, CA) following instructions. cDNA was produced from 1 μg of total RNA digested with DNaseI using the iScript cDNA Synthesis kit (Bio-Rad) according to instructions. PCR was carried out using the following primers: GFP-For (5′-TGACCCTGAACTT CATCTG-3′), GFP-Rev (5′-GCTGTTGT AGTTGTACTC-3′), RP49-For (5′-TAT GCTAAGCTGTCGCAC-3′), and RP49-Rev (5′-ATCCGTAACCGATGTTGG-3′) using DreamTaq DNA Polymerase (Fermentas Life Sciences, Glen Burnie, MD).
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Additional Supporting Information may be found in the online version of this article.

Supp. Fig. S1. Pattern of GFP expression driven by the 24B-GAL4 driver. Detection of GFP expression by in situ hybridization in embryos carrying the 24B-GAL4 driver and the UAS-GFP transgene. A, B: Lateral (A) and dorsal (B) view of a germ band--extended embryo. C, D: Lateral (C) and dorsal (D) view of a germ band--retracted embryo. GFP is expressed in the whole mesoderm.

Supp. Fig. S2. The eye phenotype caused by GATA4, Nkx2.5, TBX5, or pnr overexpression is 100% penetrant. Low-magnification images of flies overexpressing GATA4 (A), Nkx2.5 (B), TBX5 (C), or pnr (D) through the GMR-GAL4 driver at 18°C. All flies show narrow eyes.
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